Today’s Research Reports on Stocks to Watch: Mylan and Teva Pharmaceutical

NEW YORK, NY / ACCESSWIRE / February 9, 2018 / Mylan shares saw a drop in Thursday trading despite any news. The pharma giant will report its Q4 results at the end of the month. Shares of another pharma giant, Teva, were sinking into the red on their Q4 results and dismal 2018 outlook.

RDI Initiates Coverage on:

Mylan N.V.
https://rdinvesting.com/news/?ticker=MYL

Teva Pharmaceutical Industries Ltd.
https://rdinvesting.com/news/?ticker=TEVA

Mylan N.V.’s shares closed down 2.97% on about 8.1 million shares traded yesterday. The company announced earlier this month the launch of Efavirenz Tablets UPS, 600 mg, in the U.S. This is the first generic version of Bristol-Myers Squibb’s Sustiva. CEO Heather Bresch commented, “With the launch of Efavirenz, Mylan marks an important achievement in bringing more affordable treatment options to the HIV patient community. Our global commitment to improving access to antiretroviral medicines for this important patient population spans more than a decade, and the U.S. launch bolsters our leadership in producing high-quality ARVs and positions us to continue to lead this important category in the future.” The global pharmaceutical company will be releasing its fourth quarter as well as full year 2017 financial results at the end of the month on Wednesday, February 28th, after the market closes.

Access RDI’s Mylan N.V. Research Report at:
https://rdinvesting.com/news/?ticker=MYL

Teva Pharmaceutical’s shares closed in the red down 10.60% on Thursday on trading volume more than double compared to average. The Israeli pharmaceutical giant saw its shares slip after posting a quarterly loss and an outlook for 2018 that had traders less than impressed. The generic drug maker revealed it had taken a $17 billion charge against the value of its generic business in the United States. For the fourth quarter, Teva posted a $11.6 billion loss. CEO Kare Schultz also warned that this year could be as difficult as the months Teva had already been struggling but optimistically stated, “2017 was a challenging year for Teva. Starting in 2018 we are focused on meeting our financial obligations and ensuring a much more solid and sustainable business model going forward.” Looking ahead, Teva has forecast revenue in the range of $18.3 billion to $18.8 billion and non-GAAP earnings per share of $2.25 to $2.50. Both came up short compared to the $19.24 billion in revenue and adjusted EPS of $2.93 that analysts had called for. Shares of Teva are down 46% over the last twelve months.

Access RDI’s Teva Pharmaceutical Industries Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=TEVA

Our Actionable Research on Mylan N.V. (NASDAQ: MYL) and Teva Pharmaceutical Industries Limited (NYSE: TEVA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 488644